Breast cancer: Muscarinic receptors as new targets for tumor therapy

Autores
Español, Alejandro Javier; Salem, Agustina Reina; Sanchez, Yamila; Sales, María Elena
Año de publicación
2021
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
The development of breast cancer is a complex process that involves theparticipation of different factors. Several authors have demonstrated the overexpressionof muscarinic acetylcholine receptors (mAChRs) in different tumortissues and their role in the modulation of tumor biology, positioning them astherapeutic targets in cancer. The conventional treatment for breast cancerinvolves surgery, radiotherapy, and/or chemotherapy. The latter presentsdisadvantages such as limited specificity, the appearance of resistance totreatment and other side effects. To prevent these side effects, several schedules ofdrug administration, like metronomic therapy, have been developed. Metronomictherapy is a type of chemotherapy in which one or more drugs are administeredat low concentrations repetitively. Recently, two chemotherapeutic agents usuallyused to treat breast cancer have been considered able to activate mAChRs. Thecombination of low concentrations of these chemotherapeutic agents withmuscarinic agonists could be a useful option to be applied in breast cancertreatment, since this combination not only reduces tumor cell survival withoutaffecting normal cells, but also decreases pathological neo-angiogenesis, theexpression of drug extrusion proteins and the cancer stem cell fraction. In thisreview, we focus on the previous evidences that have positioned mAChRs asrelevant therapeutic targets in breast cancer and analyze the effects of administeringmuscarinic agonists in combination with conventional chemotherapeuticagents in a metronomic schedule.
Fil: Español, Alejandro Javier. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Centro de Estudios Farmacológicos y Botánicos. Universidad de Buenos Aires. Facultad de Medicina. Centro de Estudios Farmacológicos y Botánicos; Argentina
Fil: Salem, Agustina Reina. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Centro de Estudios Farmacológicos y Botánicos. Universidad de Buenos Aires. Facultad de Medicina. Centro de Estudios Farmacológicos y Botánicos; Argentina
Fil: Sanchez, Yamila. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Centro de Estudios Farmacológicos y Botánicos. Universidad de Buenos Aires. Facultad de Medicina. Centro de Estudios Farmacológicos y Botánicos; Argentina
Fil: Sales, María Elena. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Centro de Estudios Farmacológicos y Botánicos. Universidad de Buenos Aires. Facultad de Medicina. Centro de Estudios Farmacológicos y Botánicos; Argentina
Materia
CANCER
MUSCARINIC RECEPTOR
BREAST
THERAPY
Nivel de accesibilidad
acceso abierto
Condiciones de uso
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
Repositorio
CONICET Digital (CONICET)
Institución
Consejo Nacional de Investigaciones Científicas y Técnicas
OAI Identificador
oai:ri.conicet.gov.ar:11336/181217
Acceder
id CONICETDig_6811cff4441234d4daff07b32a2476d0
oai_identifier_str oai:ri.conicet.gov.ar:11336/181217
network_acronym_str CONICETDig
repository_id_str 3498
network_name_str CONICET Digital (CONICET)
spelling Breast cancer: Muscarinic receptors as new targets for tumor therapyEspañol, Alejandro JavierSalem, Agustina ReinaSanchez, YamilaSales, María ElenaCANCERMUSCARINIC RECEPTORBREASTTHERAPYhttps://purl.org/becyt/ford/3.3https://purl.org/becyt/ford/3The development of breast cancer is a complex process that involves theparticipation of different factors. Several authors have demonstrated the overexpressionof muscarinic acetylcholine receptors (mAChRs) in different tumortissues and their role in the modulation of tumor biology, positioning them astherapeutic targets in cancer. The conventional treatment for breast cancerinvolves surgery, radiotherapy, and/or chemotherapy. The latter presentsdisadvantages such as limited specificity, the appearance of resistance totreatment and other side effects. To prevent these side effects, several schedules ofdrug administration, like metronomic therapy, have been developed. Metronomictherapy is a type of chemotherapy in which one or more drugs are administeredat low concentrations repetitively. Recently, two chemotherapeutic agents usuallyused to treat breast cancer have been considered able to activate mAChRs. Thecombination of low concentrations of these chemotherapeutic agents withmuscarinic agonists could be a useful option to be applied in breast cancertreatment, since this combination not only reduces tumor cell survival withoutaffecting normal cells, but also decreases pathological neo-angiogenesis, theexpression of drug extrusion proteins and the cancer stem cell fraction. In thisreview, we focus on the previous evidences that have positioned mAChRs asrelevant therapeutic targets in breast cancer and analyze the effects of administeringmuscarinic agonists in combination with conventional chemotherapeuticagents in a metronomic schedule.Fil: Español, Alejandro Javier. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Centro de Estudios Farmacológicos y Botánicos. Universidad de Buenos Aires. Facultad de Medicina. Centro de Estudios Farmacológicos y Botánicos; ArgentinaFil: Salem, Agustina Reina. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Centro de Estudios Farmacológicos y Botánicos. Universidad de Buenos Aires. Facultad de Medicina. Centro de Estudios Farmacológicos y Botánicos; ArgentinaFil: Sanchez, Yamila. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Centro de Estudios Farmacológicos y Botánicos. Universidad de Buenos Aires. Facultad de Medicina. Centro de Estudios Farmacológicos y Botánicos; ArgentinaFil: Sales, María Elena. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Centro de Estudios Farmacológicos y Botánicos. Universidad de Buenos Aires. Facultad de Medicina. Centro de Estudios Farmacológicos y Botánicos; ArgentinaBaishideng Publishing Group2021-06info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfapplication/pdfapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/181217Español, Alejandro Javier; Salem, Agustina Reina; Sanchez, Yamila; Sales, María Elena; Breast cancer: Muscarinic receptors as new targets for tumor therapy; Baishideng Publishing Group; World Journal of Clinical Oncology; 12; 6; 6-2021; 404-4282218-4333CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/url/https://www.wjgnet.com/2218-4333/full/v12/i6/404.htminfo:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-09-03T09:45:51Zoai:ri.conicet.gov.ar:11336/181217instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-09-03 09:45:51.907CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse
dc.title.none.fl_str_mv Breast cancer: Muscarinic receptors as new targets for tumor therapy
title Breast cancer: Muscarinic receptors as new targets for tumor therapy
spellingShingle Breast cancer: Muscarinic receptors as new targets for tumor therapy
Español, Alejandro Javier
CANCER
MUSCARINIC RECEPTOR
BREAST
THERAPY
title_short Breast cancer: Muscarinic receptors as new targets for tumor therapy
title_full Breast cancer: Muscarinic receptors as new targets for tumor therapy
title_fullStr Breast cancer: Muscarinic receptors as new targets for tumor therapy
title_full_unstemmed Breast cancer: Muscarinic receptors as new targets for tumor therapy
title_sort Breast cancer: Muscarinic receptors as new targets for tumor therapy
dc.creator.none.fl_str_mv Español, Alejandro Javier
Salem, Agustina Reina
Sanchez, Yamila
Sales, María Elena
author Español, Alejandro Javier
author_facet Español, Alejandro Javier
Salem, Agustina Reina
Sanchez, Yamila
Sales, María Elena
author_role author
author2 Salem, Agustina Reina
Sanchez, Yamila
Sales, María Elena
author2_role author
author
author
dc.subject.none.fl_str_mv CANCER
MUSCARINIC RECEPTOR
BREAST
THERAPY
topic CANCER
MUSCARINIC RECEPTOR
BREAST
THERAPY
purl_subject.fl_str_mv https://purl.org/becyt/ford/3.3
https://purl.org/becyt/ford/3
dc.description.none.fl_txt_mv The development of breast cancer is a complex process that involves theparticipation of different factors. Several authors have demonstrated the overexpressionof muscarinic acetylcholine receptors (mAChRs) in different tumortissues and their role in the modulation of tumor biology, positioning them astherapeutic targets in cancer. The conventional treatment for breast cancerinvolves surgery, radiotherapy, and/or chemotherapy. The latter presentsdisadvantages such as limited specificity, the appearance of resistance totreatment and other side effects. To prevent these side effects, several schedules ofdrug administration, like metronomic therapy, have been developed. Metronomictherapy is a type of chemotherapy in which one or more drugs are administeredat low concentrations repetitively. Recently, two chemotherapeutic agents usuallyused to treat breast cancer have been considered able to activate mAChRs. Thecombination of low concentrations of these chemotherapeutic agents withmuscarinic agonists could be a useful option to be applied in breast cancertreatment, since this combination not only reduces tumor cell survival withoutaffecting normal cells, but also decreases pathological neo-angiogenesis, theexpression of drug extrusion proteins and the cancer stem cell fraction. In thisreview, we focus on the previous evidences that have positioned mAChRs asrelevant therapeutic targets in breast cancer and analyze the effects of administeringmuscarinic agonists in combination with conventional chemotherapeuticagents in a metronomic schedule.
Fil: Español, Alejandro Javier. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Centro de Estudios Farmacológicos y Botánicos. Universidad de Buenos Aires. Facultad de Medicina. Centro de Estudios Farmacológicos y Botánicos; Argentina
Fil: Salem, Agustina Reina. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Centro de Estudios Farmacológicos y Botánicos. Universidad de Buenos Aires. Facultad de Medicina. Centro de Estudios Farmacológicos y Botánicos; Argentina
Fil: Sanchez, Yamila. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Centro de Estudios Farmacológicos y Botánicos. Universidad de Buenos Aires. Facultad de Medicina. Centro de Estudios Farmacológicos y Botánicos; Argentina
Fil: Sales, María Elena. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Centro de Estudios Farmacológicos y Botánicos. Universidad de Buenos Aires. Facultad de Medicina. Centro de Estudios Farmacológicos y Botánicos; Argentina
description The development of breast cancer is a complex process that involves theparticipation of different factors. Several authors have demonstrated the overexpressionof muscarinic acetylcholine receptors (mAChRs) in different tumortissues and their role in the modulation of tumor biology, positioning them astherapeutic targets in cancer. The conventional treatment for breast cancerinvolves surgery, radiotherapy, and/or chemotherapy. The latter presentsdisadvantages such as limited specificity, the appearance of resistance totreatment and other side effects. To prevent these side effects, several schedules ofdrug administration, like metronomic therapy, have been developed. Metronomictherapy is a type of chemotherapy in which one or more drugs are administeredat low concentrations repetitively. Recently, two chemotherapeutic agents usuallyused to treat breast cancer have been considered able to activate mAChRs. Thecombination of low concentrations of these chemotherapeutic agents withmuscarinic agonists could be a useful option to be applied in breast cancertreatment, since this combination not only reduces tumor cell survival withoutaffecting normal cells, but also decreases pathological neo-angiogenesis, theexpression of drug extrusion proteins and the cancer stem cell fraction. In thisreview, we focus on the previous evidences that have positioned mAChRs asrelevant therapeutic targets in breast cancer and analyze the effects of administeringmuscarinic agonists in combination with conventional chemotherapeuticagents in a metronomic schedule.
publishDate 2021
dc.date.none.fl_str_mv 2021-06
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/11336/181217
Español, Alejandro Javier; Salem, Agustina Reina; Sanchez, Yamila; Sales, María Elena; Breast cancer: Muscarinic receptors as new targets for tumor therapy; Baishideng Publishing Group; World Journal of Clinical Oncology; 12; 6; 6-2021; 404-428
2218-4333
CONICET Digital
CONICET
url http://hdl.handle.net/11336/181217
identifier_str_mv Español, Alejandro Javier; Salem, Agustina Reina; Sanchez, Yamila; Sales, María Elena; Breast cancer: Muscarinic receptors as new targets for tumor therapy; Baishideng Publishing Group; World Journal of Clinical Oncology; 12; 6; 6-2021; 404-428
2218-4333
CONICET Digital
CONICET
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/url/https://www.wjgnet.com/2218-4333/full/v12/i6/404.htm
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.format.none.fl_str_mv application/pdf
application/pdf
application/pdf
application/pdf
application/pdf
dc.publisher.none.fl_str_mv Baishideng Publishing Group
publisher.none.fl_str_mv Baishideng Publishing Group
dc.source.none.fl_str_mv reponame:CONICET Digital (CONICET)
instname:Consejo Nacional de Investigaciones Científicas y Técnicas
reponame_str CONICET Digital (CONICET)
collection CONICET Digital (CONICET)
instname_str Consejo Nacional de Investigaciones Científicas y Técnicas
repository.name.fl_str_mv CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas
repository.mail.fl_str_mv dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar
_version_ 1842268758384574464
score 13.13397

Publicaciones similares